In this study, we evaluated the role of signal transducer and activator of transcription 1 (STAT1) in response to acute solar ultraviolet (SUV) radiation in mouse epidermis.
6.5-fold with metastatic SCC. 8 DNA damage and generation of reactive oxygen species (ROS) are hallmarks of NMSC development due to SUV radiation. 9 SUV radiation can directly (via pyrimidine dimer and 6-4 photoproduct formation) cause DNA damage 9, 10 or indirectly through the production of ROS which leads to increased mutational burden in a number of critical genes. [11] [12] [13] SUV radiation is made up of three types: UVA (315-400 nm), UVB (280-315 nm), and UVC (190-280 nm). 9 Among these, only UVA and UVB are relevant for the induction of skin cancer. UVA is primarily involved in causing ROS production, 14 while UVB is primarily involved in causing DNA damage, 9 although UVA can lead to DNA damage and UVB, can lead to ROS production. 9, 15 Induction of ROS by UVA and UVB also plays a significant role in activating cellular signaling pathways such as ERK, JNK, p38, and activating transcription factors including NFκB, AP-1, c-FOS, and c-JUN. [15] [16] [17] Due to these pleiotropic effects of DNA damage, ROS induction, and signaling pathway activation, in addition to possessing potent immunosuppressive activities, 9 UVA and UVB both function as initiators and promoters of skin carcinogenesis although UVB is a more potent carcinogen. 18 Signal transducer and activator of transcription 1 (STAT1) is the prototypical member of the STAT family. 19 STAT1 transduces signals from cell surface receptors and receptor-associated kinases called Janus Kinases (JAKs). STAT1 is primarily activated by type I-III interferons (IFNs) and serves as a key player in innate and adaptive immunity and protects against viral and bacterial infections. 20 Upon activation, STAT1 is phosphorylated on conserved tyrosine (tyr701) and serine (ser737) residues within the carboxy-terminal transactivation domain that triggers dimerization, resulting in translocation to the nucleus and regulation of target gene expression. [21] [22] [23] More recently, it has been found that STAT1 can also mediate gene expression in the absence of tyrosine (tyr701) phosphorylation (unphosphorylated STAT1 or uSTAT1) 24, 25 by prolonging the response of cells to IFN and maintaining or increasing expression of a subset of these genes. 26 Activated STAT1 (referred to as pSTAT1) has been classically defined as antitumorigenic by modulating key components of tumor immune surveillance, [27] [28] [29] inducing proapoptotic regulators such as Fas/FasL and caspases and by regulating negative cell cycle proteins, such as p21. [30] [31] [32] In this regard, studies have shown that STAT1 expression is frequently lost in human cancers and cell lines, such as colon cancer, 33 pancreatic cancer, 34 esophageal cancer, 35, 36 and breast cancer 37 and its inhibition in various mouse models can enhance the growth of cancer cells and make susceptible to tumor formation. 38, 39 However, protumorigenic functions have also been ascribed to STAT1 by modulating cell growth and invasion, immune suppression, and therapy resistance. 19 In this regard, constitutive STAT1 activation and/or overexpression of IFN-related genes in breast cancers are associated with poor prognosis. 40, 41 Furthermore, studies have also shown a protumorigenic role of STAT1 signaling in melanoma, 42, 43 colon cancer, 44, 45 esophageal cancer, 35 and leukemia. 46 Taken together, emerging evidence has led to the concept that STAT1 can elicit both tumor-suppressive and protumorigenic effects in tissue and context-dependent manner.
Previous studies from our laboratory have demonstrated that STAT3 plays an important role in both chemical-and UVB-induced skin carcinogenesis by regulating both the initiation and promotion stages of tumor development through regulation of cell growth and survival of keratinocyte stem cells. [47] [48] [49] [50] However, the exact role of STAT1 (and other STATs) in skin carcinogenesis remains to be fully investigated. Recently, we reported that STAT1 is absolutely required for tumor development in a two-stage chemical carcinogenesis protocol using the tumor promoter, 3-methyl-1,8-dihydroxy-9anthrone (chrysarobin or CHRY), 51 but was dispensable for tumor development using the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA). CHRY treatment led to rapid STAT1 phosphorylation at tyr701 and ser727 and induction of interferon regulatory factor 1 (IRF-1) while later timepoints showed increased uSTAT1 protein levels. Furthermore, STAT1 activation was also dependent on IFNγ receptor (IFNγR) signaling. These initial studies defined a novel mechanism associated with skin tumor promotion by the anthrone class of tumor promoters (eg CHRY), and also demonstrated a critical role for IFNγ/pSTAT1/ IRF-1/uSTAT1 signaling during two-stage skin carcinogenesis using certain types of tumor promoters.
Here, we report for the first time that SUV radiation activates the pSTAT1/IRF-1/uSTAT1 signaling specifically in keratinocytes in vivo in an IFNγ-dependent manner. In addition, we provide evidence that STAT1 is activated in keratinocytes via IFNγ produced by skinresident CD3+T-cells, and that keratinocyte-specific STAT1 is required for SUV-induced hyperplasia, proliferation, and dermal inflammation. Taken together, the current data suggest that activation of the IFNγ/pSTAT1/IRF-1/uSTAT1 signaling pathway plays an important role in the early stages of SUV-mediated skin carcinogenesis and may represent a novel target for prevention of nonmelanoma skin cancer. were purchased from The Jackson Laboratory. The IFNγR -/mice were on a C57BL/6 genetic background and so C57BL/6 wild-type mice were used as control mice for experiments using IFNγR −/− mice.
| MATERIALS AND METHODS

| Animals and treatments
SUV was emitted in a chamber containing 12 Sylvania FS20T12/ 350BL lamps. The mice were shaved on their dorsal regions 2 days before SUV treatment. Each mouse was kept in individually enclosed BLAZANIN ET AL.
| 1657
cells with plastic cover allowing the transmission of SUV during the treatment. The enclosed mice were placed on a rotating platform that ensures evenly exposed doses. The mice were treated every 2 days for four treatments total and each application took approximately 4.5-5 hours to reach the dose of 28 J/cm 2 UVA+1.9 J/cm 2 UVB at a ratio of UVA/UVB approximately comparable to natural sunlight. 52 
| Western blot analysis
After treatment, the mice were killed by cervical dislocation and the dorsal skins were treated briefly with a depilatory agent (Nair, Church & Dwight Co.). Epidermal lysates were prepared from excised dorsal skin in RIPA lysis buffer and protease inhibitor cocktail, phosphatase inhibitor cocktail 2 and phosphatase inhibitor cocktail 3 (Sigma-Aldrich) as described. 53 Protein quantitation of epidermal lysates was measured by DC Protein Assay kit (Bio-Rad Laboratories). Epidermal lysates were separated on SDS-PAGE gels under reducing conditions. The separated proteins were then transferred onto nitrocellulose membranes (Bio-Rad Laboratories) and blocked for 1 hour in 5% nonfat dried milk at room temperature followed by overnight incubation with specific primary antibodies at 4°C. After washing with TBST containing 0.1% Tween-20, blots were subjected to horseradish peroxidase-conjugated secondary antibodies and visualized using chemiluminescence detection (Pierce ECL Western Blotting Substrate). Protein quantitation was determined by Image J software using Vinculin (Cell Signaling) as internal control. Primary antibodies against the following proteins were used: STAT1, STAT3, IRF-1, p-STAT1 Y701 , p-STAT1 S727 , p-STAT3 Y705 , (all Cell Signaling), and COX-2 (Cayman Chemical).
| RNA isolation and qPCR
Epidermal lysates were homogenized in RLT buffer (Qiagen) before snap freezing. Total RNA was extracted using the RNeasy Mini Kit 
| Statistical analyses
| SUV exposure activates the pSTAT1/IRF-1/uSTAT1 pathway in the epidermis
Wild-type FVB/N mice were treated with SUV every 2 days for a total of four treatments and STAT1 protein and phosphorylation levels were examined in epidermal protein lysates at different time points after the last treatment. As shown in Figure 1A , the level of STAT1 phosphorylation at tyr701 rapidly increased as early as 3 hours after the last SUV treatment in the epidermis of wild-type mice when compared with sham-treated control mice. STAT1 phosphorylation at tyr701 was highest at 6 hours and remained elevated at 24 hours after exposure although to a lesser extent ( Figure 1A) . Similarly, after SUV exposure phosphorylation of STAT1 at ser727 was elevated with a timecourse similar to tyr701. STAT1 protein levels were consistently increased as early as 3 hours and remained elevated 24 hours after the last SUV treatment ( Figure 1A ).
This increase in STAT1 at later timepoints occurred when phosphorylation levels were decreased ( Figure 1A and 1B), indicating that a significant portion of total STAT1 at 24 hours after SUV treatment was unphosphorylated (ie, uSTAT1). These results are similar to our previous results showing that topical application of CHRY caused activation of this pathway with induction of uSTAT1 in the epidermis. 51 Phosphorylated STAT1 transcriptionally regulates a number of genes including both STAT1 and IRF-1. 54,55 IRF-1 is an IFNγ/pSTAT1 responsive transcription factor known to regulate expression of many immune-function genes, including enhancing expression of those induced by pSTAT1; IRF-1 can also upregulate uSTAT1. 56 SUV exposure upregulated IRF-1 protein levels in epidermis as early as 3 hours after treatment similar to changes in STAT1 phosphorylation at tyr701 and ser727 ( Figure 1A and 1B ). Next, we investigated if IRF-1 induction was directly mediated by STAT1 activation by evaluating similar changes in STAT1 KO mice after exposure to SUV.
As shown in Figure S1A and B, increased phosphorylation of STAT1 at tyr701 and ser727 as well as increased IRF-1 and uSTAT1 protein levels were not observed in epidermal lysates of STAT1 KO mice after exposure to SUV. Taken together, these results indicate that repeated SUV treatments caused activation of pSTAT1 and induction of both IRF-1 and uSTAT1 in the epidermis after exposure to SUV. In the absence of STAT1, there was no induction of IRF-1.
| Keratinocyte-specific deletion of STAT1 abrogates activation of the pSTAT1/IRF-1/uSTAT1 signaling pathway in epidermis after SUV treatment
To further confirm the results described above, activation of the pSTAT1/IRF-1/uSTAT1 pathway was evaluated in the epidermis of BK5.Cre x STAT1 flox/flox mice (keratinocyte-specific deletion of STAT1) after exposure to SUV. All of our previous experiments used total body STAT1 KO mice 51 ( Figure S1 ). Wild-type FVB/N mice were used as control mice for these experiments. In wild-type mice, SUV treatment led to the expected STAT1 activation in epidermis (ie phosphorylation at tyr701 and ser727) at 6 hours after the last treatment, but decreased by 24 hours while IRF-1 and uSTAT1 protein levels were increased at 6 and 24 hours (Figure 2A and 2B).
However, in keratinocyte-specific STAT1-deficient mice phosphorylation of STAT1 and induction of IRF-1 and uSTAT1 protein levels in epidermis were markedly diminished similar to the results seen in mice with total body STAT1 KO mice ( Figure S1 ). SUV also increased STAT3 phosphorylation (pSTAT3) on tyr705 as early as 6 hours after the last treatment (Figure 2A and 2B) similar to our previous results following exposure to UVB. 57 However, no increase in uSTAT3 was observed. Furthermore, activation of STAT3 (ie, phosphorylation at tyr705) was not affected when STAT1 was deleted in keratinocytes indicating that the mechanism for STAT3 activation is distinct from STAT1 activation following SUV exposure. Previous studies from our laboratory have shown that STAT3 is activated downstream of the EGFR in mouse keratinocytes. 58 Taken together, these data demonstrate that SUV treatment led to the activation of the pSTAT1/IRF-1/uSTAT1 specifically in keratinocytes and that the F I G U R E 1 STAT1/IRF-1 signaling is activated in the epidermis of SUV-treated mice. Wild-type FVB/n mice were exposed to SUV (28 J/cm 2 UVA+1.9 J/cm 2 UVB) four times every other day and killed at different time points after the last treatment. A, Western blot analysis of epidermal lysates in untreated and SUV-treated wild-type mice examining p-STAT1 Y701 , p-STAT1 S727 , STAT1, IRF-1 and vinculin protein levels at indicated time points. The STAT1 antibodies recognize both STAT1α (91 kDa) and STAT1β (84 kDa) isoforms both of which are present in the Western blots of epidermal protein lysates. Western blot images are a single representative experiment using pooled protein samples (n = 3-5 mice/group). B, Quantitation of total protein levels in (A) by densitometry. Vinculin was used to normalize protein loading. Values shown in (B) are the mean ± SEM of three independent experiments. * indicates values significantly different from the sham-treated STAT1 (+/+) control group (P < 0.05). IRF-1, interferon regulatory factor 1; SEM, standard error of the mean; STAT1, signal transducer and activator of transcription 1; SUV, solar ultraviolet mechanism for activation of this pathway is distinct from pathways leading to activation of STAT3.
| STAT1 activation in keratinocytes regulates expression of inflammatory genes in SUV-treated mice
Further analyses were undertaken to explore whether keratinocytespecific STAT1 and downstream IRF-1 signaling regulated expression of key mediators of the inflammatory response in the epidermis following SUV treatment. For these experiments, both wild-type and BK5.Cre x STAT1 flox/flox mice were compared. As noted previously, pSTAT1 and IRF-1 are known to regulate a vast number of inflammation/immune-related genes including members of the CXCLand CCL-families. 19 As shown in Figure 3A , analysis of epidermal lysates from wild-type mice treated with SUV showed increased The pSTAT1/IRF-1 signaling pathway also regulates the expression of PD-L1, a critical immune checkpoint inhibitor that regulates tumor immune suppression. 19, 59, 60 Indeed, analysis of epidermal lysates indicated that Pd-l1 mRNA levels increased by almost 3-fold as early as 6 hours after the last SUV treatment in wild-type mice; a time course similar to the other chemokines examined ( Figure 3A ).
However, this induction of Pd-l1 mRNA levels by SUV was absent in epidermis of BK5.Cre x STAT1 flox/flox mice. As shown in Figure 3B , SUV treatment also led to a 6-fold increase in epidermal Cox-2 mRNA levels at 6 hours after the last treatment. Cox-2 mRNA levels returned to basal levels by 24 hours after the last treatment when compared to sham-treated control mice ( Figure 3B ). In contrast, Cox-2 mRNA levels were not increased in the epidermis of BK5.Cre x STAT1 flox/flox mice following treatment with SUV ( Figure 3B ). COX-2 protein levels also exhibited a similar pattern ( Figure 3C and 3D), indicating that keratinocyte-specific STAT1 has an essential role in regulating COX-2 expression in the epidermis in response to SUV.
Note that two bands corresponding to COX-2 protein (lower two bands) were observed in epidermal protein lysates from the mice treated with SUV in Figure 3C In previous studies, we demonstrated that IFNγ mRNA levels were increased in the epidermis in response to topical treatment with CHRY, a nonphorbol ester skin tumor promoter and that IFNγR1 signaling was essential for activation of the pSTAT1/IRF-1/uSTAT1 pathway in the epidermis. 51 To investigate whether increased STAT1 phosphorylation at tyr701 and ser727 may be due to activation of this pathway in SUV-exposed skin, we first analyzed epidermal IFNγ mRNA levels at different time points. As shown in Figure 4A , IFNγ mRNA levels were increased approximately 20-fold as early as 3 hours after the last SUV treatment and remained significantly elevated at both 6 (~15-fold) and 24 hours (~20-fold) after the last treatment with SUV. To further establish a connection between increased IFNγ expression and activation of the pSTAT1/IRF-1/ uSTAT1 signaling pathway, IFNγR1 KO mice were subjected to the same SUV treatment protocol. As expected, SUV-induced STAT1 phosphorylation at tyr701 and ser727 in wild-type mice as early as 6 hours after the last treatment that returned to levels observed in sham-treated control mice after 24 hours while both IRF-1 and total STAT1 protein levels were increased at 6 and 24 hours ( Figure 4B and 4C). Importantly, in the epidermis of IFNγR1 KO mice, STAT1 phosphorylation at tyr701 and ser727 was significantly reduced as was the protein levels of IRF-1 and total STAT1. These data indicate that the pSTAT1/IRF-1/uSTAT1 pathway activation in response to SUV treatment is dependent on an intact IFNγR1 in keratinocytes.
The specificity of STAT1 activation through IFNγR1 was further confirmed as SUV-induced STAT3 phosphorylation at tyr705 and STAT3 protein levels were similar at 6 and 24 hours in both wild-type and IFNγR1-deficient mice (data not shown).
The impact of IFNγR1 KO on the expression of inflammatory genes was also examined. All the inflammatory genes that were examined in keratinocyte-specific STAT1-deficient mice (Figure 3) were evaluated in IFNγR1 KO mice. As shown in Figure 5A , Cxcl9, Cxcl10, Ccl2, and Pd-l1 mRNA levels were significantly higher in the epidermis of wild-type mice compared with IFNγR1-deficient mice 6 hours after the last SUV treatment. Cxcl9 and Cxcl10, mRNA levels returned to baseline similar to sham-treated control C57BL/6 mice after 24 hours. However, Ccl2 mRNA levels were further increased 24 hours after the last SUV treatment in these mice ( Figure 5A ).
Regardless of the difference in induction kinetics, all inflammatory
chemokine mRNA levels were significantly decreased in the absence of a functional IFNγR1. Pd-l1 mRNA levels also exhibited a similar expression pattern as Ccl2 mRNA levels after SUV treatment, that was also dependent on a functional IFNγR1 for induction ( Figure 5A ). 
Analysis of
| Skin-resident CD3+T-cells rapidly upregulate IFNγ expression after treatment with SUV
The IFNγ gene is tightly regulated and almost exclusively produced by cells of the immune system such as CD4+T-helper cells (Th1),
CD8+cytotoxic T-cells, B-cells, natural killer (NK) cells, and antigenpresenting cells. [63] [64] [65] [66] [67] To ascertain the source of IFNγ production, we employed an IFNγ reporter mouse which has an IRES-eYFP reporter cassette inserted between the translational stop codon and 3' UTR/ polyA tail of the IFNγ gene. 68 Figure S2 ). Because our previous studies showed that treatment of mouse skin with CHRY also required an intact IFNγR1 signaling pathway we also treated IFNγ reporter mice with this tumor promoter. IFNγ-producing CD3+T-cells were also detected in the epidermis when IFNγ reporter mice were topically treated with CHRY (data not shown). Again, IFNγ-producing cells were detected in the dermal compartment but most were not CD3+T-cells, indicating that other immune cells may express IFNγ when treated with CHRY.
Taken together, these data, as well as our previously published data, 51 Figure 6B ). In contrast, the epidermal thickness was significantly decreased at 24 hours after the last SUV treatment in BK5.Cre x STAT1 flox/flox mice (again see Figure 6A 
| DISCUSSION
In the current study, we have shown that exposure of mouse skin to SUV leads to activation of STAT1 signaling in the epidermis.
Activation of STAT1 (phosphorylation at tyr701 and ser727) was accompanied by upregulation of IRF-1 protein, a known STAT1 F I G U R E 5 IFNγR1 deficiency regulates proinflammatory gene expression and COX-2 following SUV treatment. IFNγR1 (+/+) and IFNγR1 (−/−) mice were exposed to SUV four times (28 J/cm 2 UVA + 1.9 J/cm 2 UVB) every other day and killed at different time points after the last treatment. A, qPCR analysis of epidermal lysates in untreated and SUV-treated mice examining Cxcl9, Cxcl10, Ccl2, and Pd-l1 mRNA levels at of IRF-1. The STAT1 gene is a known target of IRF-1 and it is now established that activation of this pathway leads to upregulation uSTAT1. 54, 55 We further established that SUV exposure led to upregulation of IFNγ and that activation of the pSTAT1/IRF-1/ uSTAT1 signaling pathway in epidermal keratinocytes was dependent on a functional IFNγR1. Further analyses revealed that SUV activation of this signaling pathway in keratinocytes controlled the expression of several chemokines and immune modulators known to be regulated by IFNγ signaling, including Cxcl9, Cxl10, Ccl2 and Pd-l1. 19, 59 In addition, induction of epidermal COX-2 after exposure to SUV was also dependent on this signaling pathway. Finally, we found that epidermal proliferation and inflammation following SUV exposure was also, at least partially, dependent on keratinocyte STAT1 signaling. Collectively, these studies provide strong evidence for a tumor-promoting/protumorigenic role of IFNγ/pSTAT1/IRF-1/ uSTAT1 signaling in keratinocytes after exposure to SUV.
It is notable that activated STAT1 (p-STAT1) has been associated with antitumorigenic or tumor suppressive properties by modulating key components of immune tumor surveillance, 27, 28, 70 inducing proapoptotic regulators, such as Fas/FasL and caspases and by regulating negative cell cycle proteins such as p21 and p27. 30 STAT1 is considered an indispensable upstream regulator of IFN signaling, as STAT1-deficient cells are unresponsive to both Type I and Type II IFNs. 20 Due to impaired IFN signaling, STAT1-deficient mice are highly susceptible to both viral and bacterial infection. 20 Several studies have supported an antitumorigenic role for STAT1. In this regard, STAT1 activation has been associated with both antiproliferative as well as proapoptotic effects in cancer. 30, 32, 71, 72 Furthermore, Kaplan et al 38 breast cancers associated with poor prognosis and resistance to radiation and adjuvant cancer therapy. 40, 41 In fact, a role for STAT1 in promotion of leukemia development has been reported 73 and several researchers have also proposed a protumorigenic role of IFNγ-STAT1 signaling in melanoma. 42, 43 We previously reported that topical treatment with the nonphorbol ester skin tumor promoter, CHRY, activated the IFNγ/ pSTAT1/IRF-1/uSTAT1 signaling pathway in epidermis and that STAT1-deficient mice (ie, total body STAT1 KO mice) were resistant to skin tumor promotion by this compound following initiation with 7,12,dimethylbenz[a]anthracene. 51 In contrast, the phorbol ester skin tumor promoter, TPA, did not activate the IFNγ/pSTAT1/IRF-1/ uSTAT1 signaling pathway in the epidermis and thus STAT1 was dispensable for tumor promotion by this compound. A distinctive difference between phorbol ester tumor promoters, such as TPA is that the cellular receptor that initiates their mechanism of action is protein kinase C (PKC) 74, 75 whereas nonphorbol ester tumor promoters such as anthrones (eg, CHRY) do not activate PKC, but rather undergo autoxidation to generate reactive intermediates and generate reactive oxygen species (ROS) causing oxidative stress that can activate multiple signaling pathways associated with skin tumor promotion. 76 Induction of ROS also plays a prominent role in the effects of SUV radiation and regulates activation of multiple signaling pathways 15, 17 several of which are common between certain chemical tumor promoters such as CHRY. 77, 78 Therefore, a common ROS-mediated mechanism may be shared between certain classes of tumor promoters and SUV in regulating IFNγ/pSTAT1/IRF-1/uSTAT1 signaling during the tumor promotion phase of skin carcinogenesis.
Collectively, the data from our previous and current studies suggest that activation of the IFNγ/pSTAT1 /IRF-1/uSTAT1 signaling pathway in keratinocytes leads to protumorigenic effects for certain tumor promoters as well as SUV.
The mechanism(s) underlying protumorigenic effects of the IFNγ/ pSTAT1/IRF-1/uSTAT1 signaling pathway in skin carcinogenesis remain to be fully elucidated. In our previous work with CHRY, we found that STAT1 −/− mice treated with this tumor promoter had a reduced proliferative response that contributed to the inhibition of skin tumor promotion seen in these mice. 51 However, IFNγ and STAT1 signaling is known to regulate the production of proinflammatory molecules such as iNOS and COX-2 (59, 60) and to upregulate a variety of inflammatory mediators and immune regulatory molecules. 19, 79 In these previous studies, CHRY treatment led to upregulation of epidermal COX-2 and iNOS expression (both mRNA and protein) that was dependent on IFNγ/pSTAT1/IRF-1 signaling. The induction of COX-2 and the increased production of prostaglandins, such as PGE2 represent important events in the process of skin tumor promotion 28, 69, 70 and UV skin carcinogenesis. 80 Therefore, the IFNγ/pSTAT1/IRF-1 regulation of the induction of COX-2 and iNOS by CHRY may also explain, at least in part, some of the protumorigenic effects associated with this pathway and skin tumor promotion by CHRY. As seen in Figures 3 and 5 of the current study, SUV exposure also led to induction of COX-2, as expected based on other data in the literature. [80] [81] [82] The upregulation of epidermal COX-2 was significantly reduced in both keratinocytespecific STAT1-deficient mice as well as IFNγR1 −/− mice compared with wild-type mice treated with SUV. These findings indicate that the IFNγ/pSTAT1/IRF-1 signaling pathway also plays an important role in regulating the COX-2 expression during exposure to SUV providing a similar protumorigenic function via upregulation of PGE2 and other eicosanoids.
Inflammation plays an important role in skin carcinogenesis and tumor promotion. 83, 84 SUV exposure was found to increase mRNA expression of several chemokines/immune modulators in the epidermis known to be regulated by IFNγ signaling (as noted above), including Cxcl9, Cxcl10, Ccl2, and Pd-l1. These changes were observed in addition to the upregulation of COX-2 induction and may have also contributed to the inflammation associated with SUV exposure.
CXCL9 and CXCL10 are chemokines that bind to CXCR3 leading to the recruitment of tumor-suppressive T cells and NK cells into tumor stroma. [85] [86] [87] [88] [89] Higher concentrations of these chemokines in tumors is associated with a higher lymphocyte infiltration and better overall survival in ovarian and other cancers. [90] [91] [92] [93] [94] [95] In contrast, other studies have suggested a protumorigenic role of these two chemokines in cancer progression and metastasis. [96] [97] [98] This protumorigenic effect may be due, at least in part, to overexpression of CXCR3 in tumor cells leading to hyperactivation of signaling pathways. 99, 100 Ccl2 mRNA was also significantly upregulated in epidermal RNA samples after SUV exposure. CCL2 and its receptor CCR2 have been shown to play important roles in cancer metastasis by promoting cell proliferation and survival, stimulating cancer cell migration and invasion, and inducing inflammation and angiogenesis. 101 Although further work is required, the current data suggest that upregulation of various chemokines via keratinocyte-specific STAT1 activation plays a role in the inflammatory response to SUV during the early stages of skin carcinogenesis.
Another interesting observation from the current study was the novel finding that SUV exposure led to significant upregulation of Pd-l1 mRNA in the epidermis. PD-L1 is a known IFNγ regulated gene that plays a role in suppressing cytotoxic T-cell function. 102 PD-L1 binding to its receptor, PD-1, on the surface of T-cells leading to eventual T-cell exhaustion and ineffective T-cell function. 102 As shown in Figures 3 and 5 , SUV-induced Pd-l1 mRNA expression was dependent on functional IFNγ/pSTAT1/IRF-1 signaling in keratinocytes. UV-induced immune suppression in skin carcinogenesis is a well known phenomenon that has been widely studied and involves a number of alterations. 9 In animal models, UV-induces systemic immunosuppression involves the development of antigen-specific regulatory T-cells (CD4+CD25+foxp3+cells), which can be transferred into nonexposed animals. 103, 104 While further work is necessary, upregulation of PD-L1 after exposure to SUV may play an important role in local immune suppression during skin carcinogenesis.
Finally, another interesting aspect of the current study involved experiments to identify the cells producing IFNγ in the epidermis after exposure to SUV. For these experiments, we used IFNγ reporter mice. 68 Exposure of these mice to SUV revealed that skin resident CD3+T-cells located at epidermal-dermal junctions and in the dermis were the likely source of IFNγ production immediately following SUV (as early as 1 hour after last treatment). As an extension of our previous study with CHRY, 51 we also observed that following topical application of CHRY (as early as 6 hours after last treatment) skin resident CD3+T-cells at epidermal-dermal junctions were IFNγproducing cells (data not shown). Thus, the rapid induction of IFNγ in the epidermis and downstream activation of pSTAT1/IRF-1/ uSTAT1 signaling in keratinocytes by both SUV and CHRY appears to be dependent on skin-resident T-cells present before treatment.
Further experiments will be required to determine the T-cell subset that is producing IFNγ after exposure of skin to SUV.
In conclusion, the current studies demonstrate that exposure of mouse skin to SUV leads to activation of the IFNγ/pSTAT1/IRF-1/ uSTAT1 signaling pathway in epidermal keratinocytes. This pathway appears to regulate both epidermal proliferation, as well as dermal inflammation through the production of various inflammatory mediators. It is also interesting to speculate that this pathway may mediate local immune suppression during the early stages of skin carcinogenesis. Based on the current data, as well as our previous studies with the nonphorbol ester tumor promoter CHRY, we propose that this pathway plays a protumorigenic role during the early stages of skin carcinogenesis.
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